Active ingredientErdafitinibCat. No. P-E078-001CAS 1346242-81-6Family · Pharmaceutical analytical standards
Erdafitinib
An oral FGFR inhibitor, approved in the United States in 2019 (under accelerated approval, made full in 2024) and in Europe in 2024 for advanced urothelial carcinoma with FGFR3 gene alterations. This family brings together the active ingredient, nitrosamines and other impurities.
Did you know?The FDA regarded it as a 'first-in-class' medicine, and it was approved together with a 'companion' genetic test that looks for FGFR3 or FGFR2 alterations in the tumour.
Go to the active ingredient →Active ingredientErdafitinibCat. No. P-E078-001CAS 1346242-81-6
NitrosamineN-Nitroso ErdafitinibCat. No. P-E078-004
ImpurityErdafitinib Impurity 1Cat. No. P-E078-005No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.